Sano, D., Bartlett, N., Budde, E., Brinker, B., Vaidya, R., Babu, S., Diefenbach, C., Nze, C., Ma, C., Knapp, A., Doral, M., Chen, V., Hauser, P., Wei, M. C., Moorthy, P., Phillips, A., Surh, N., Jan, A., Purev, E., Wagner-Johnston, N. (2025). Promising response rates and manageable safety with mosunetuzumab plus lenalidomide (Mosun-Len) in patients with relapsed/refractory (R/R) follicular lymphoma (FL): US extension cohort from the Phase III CELESTIMO study. Blood. https://doi.org/10.1182/blood-2025-1800